Materials for treating and preventing mucosa related disease

Abstract

Provided is a hyaluronic acid (HA) composition for use in treating or preventing mucosa related disorders or diseases including a mixture of HAs having different average molecular weights and different rheological, isolation, tissue scaffold and degradation properties. The resulting formulation demonstrates an optimal balance between adhesion, tissue scaffold and treating time on the treatment and prevention of mucosa related disorders or diseases including conjunctivitis, otitis, allergic rhinitis, gingivitis, oral ulcer, bronchitis, gastroesophageal reflux disease (GERD), esophagitis, gastritis, enteritis, peptic ulcer, inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), urethritis, cystitis and vaginitis.

Description

BACKGROUND OF THE INVENTION[0001]1. Field of the Invention[0002]The present invention provides a composition of hyaluronic acids for treating and preventing mucosa related disorders or diseases whereas the symptoms include ulceration, inflammation, allergic reaction and bleeding.[0003]2. Description of the Prior Arts[0004]Hyaluronic acid, also known as hyaluronan, hyaluronate and sodium hyaluronate, is generally referred to as HA, which is a natural glycosaminoglycan macromolecule including disaccharides composed of the alternative N-acetyl-D-glucosamine and D-glucuronic acid linked via alternative β-1,3 and β3-1,4glycosidic bonds. HA found in nature with a molecular weight (Mw) between 50,000 Dalton (Da) and a few million Dalton usually has high viscosity.[0005]HA found in nature is the fluid with elasticity, filling between the cells and the collagenous fibers and covering onto some epidermal tissues, mainly for protecting and lubricating cells, for providing a platform for transp...

AI Technical Summary

Benefits of technology

The present invention provides a method for treating mucosa related disorder by administering a therapeutically effective amount of a mixture of hyaluronic acid compositions with different average molecular weights. The low molecular weight hyaluronic acid (LMWHA) and high molecular weight hyaluronic acid (HMWHA) have different functions and degradation rates, which make them ideal for treating various mucosal disorders. The LMWHA quickly covers the inflammatory surface, while the HMWHA provides a longer effective period. The mixture of LMWHA and HMWHA can achieve faster treatment and sustained release effect.

Problems solved by technology

For example, HA with the average molecular weight of 650 kDa or 1,900 kDa is used to treat the cystitis; however, the single species of HA with the certain average molecular weight cannot be used for both prompt treatment and sustained effect.

However, hyaluronic acid and hyaluronate with merely one average molecular weight could not cover both the immediate and sustained functions in the treating effect after being injected into the patient, therefore, it is very inconvenient for patients clinically.

However, the referenced patent only uses one species of HA with a certain average molecular weight, lacking in both quick and long term effects simultaneously.

While allergic rhinitis is not a life-threatening condition, complications can occur and the condition can significantly impair quality of life, which leads to a number of indirect costs (referring to Bousquet J et al.

Therefore, it did not disclose or teach combining HAs with two different average molecular weights.

The challenge is to allow efficient transport of nutrients across the epithelium while rigorously excluding passage of harmful molecules and organisms into the animal.

In general, toxins and microorganisms that are able to breach the single layer of epithelial cells have unimpeded access to the systemic circulation.

However, such treatments are mostly achieved by drug with complicated composition through highly specialized preparation processes and not by a simple and safe treatment.

Images